# Fibroblast–immune crosstalk in oral squamous cell carcinoma: from tumor promotion to immune evasion

**Authors:** Xiao Liu, Dandan Wang, Xue Cheng, Yining Ma, Siya Li, Jinhai Deng, Chunyan Qiao

PMC · DOI: 10.3389/fimmu.2025.1703277 · 2026-01-09

## TL;DR

This review explores how fibroblasts and immune cells interact in oral cancer, promoting tumor growth and resistance to treatment.

## Contribution

The paper highlights CAF heterogeneity and their role in immune evasion, offering new insights for improving immunotherapy.

## Key findings

- CAFs modulate immune surveillance by recruiting regulatory T cells and promoting macrophage polarization.
- CAFs contribute to therapy resistance through secreted factors like cytokines and exosomal miRNAs.
- Crosstalk via IL-6–STAT3–PD-L1 and CXCL12–CXCR4 axes promotes immune evasion in OSCC.

## Abstract

Oral squamous cell carcinoma (OSCC) is a highly invasive malignancy marked by poor prognosis and therapeutic resistance. Within its tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) and immune cells form a dynamic network that drives tumor progression. CAFs reshape the extracellular matrix, rewire tumor metabolism, and modulate immune surveillance by recruiting regulatory T cells and promoting macrophage polarization. Recent studies have highlighted CAF heterogeneity, identifying functionally distinct subtypes with differential impacts on prognosis and treatment responsiveness. CAF-derived secretomes, including cytokines, chemokines, and exosomal miRNAs, shape tumor–immune dynamics and mediate resistance to cisplatin and anti-angiogenic therapies. Crosstalk between CAFs and immune cells, particularly via the IL-6–STAT3–PD-L1 and CXCL12–CXCR4 axes, promotes immune evasion and dampens responses to checkpoint blockade. This review summarizes the phenotypic heterogeneity, metabolic functions, and secretory profiles of CAFs in OSCC, with particular emphasis on their crosstalk with immune components, highlighting the potential of CAFs-targets to enhance immunotherapy responsiveness.

## Linked entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], CD274 (CD274 molecule) [NCBI Gene 29126], CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387], CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852]
- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** oral squamous cell carcinoma (MONDO:0004958)

## Full-text entities

- **Genes:** CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** OSCC (MESH:D000077195), invasive (MESH:D009361), cancer (MESH:D009369)
- **Chemicals:** cisplatin (MESH:D002945)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12827624/full.md

---
Source: https://tomesphere.com/paper/PMC12827624